Annual Report 2017

Takahiro Fukuda, Sung-Won Kim, Saiko Kurosawa, Yoshihiro Inamoto, Takashi Tanaka, Ayumu Ito, Tomonari Takemura

Introduction

 At the National Cancer Center Hospital (NCCH), the Department of Hematopoietic Stem Cell Transplantation (HSCT) specializes in patients who undergo allogeneic or autologous HSCT. Twenty-six beds in ward 12B and additional three beds in ward 11A, which are filtered by a central high-efficiency particulate air filtration system, are solely dedicated to our Transplant Unit.

Routine activities

 Seven staff physicians (Drs. Kim, Kurosawa, Inamoto, Tanaka, Ito, Takemura, and Fukuda) and two chief residents (Drs. Kawajiri and Kuno) participate in the transplant program. Children who have undergone HSCT are managed in collaboration with Dr. Ogawa, the chief of the Department of Pediatric Oncology, and the transplant team. In 2017, a total of 106 transplantations were performed at the 12B and 12A transplant units. The numbers of each type of HCST in 2017 are shown in Table 1, and the numbers of patients according to disease types are shown in Table 2.

 At the weekly conference on Monday afternoons, in collaboration with doctors of the

Table 1. Number of each type of HSCT in 2017

Table 1. Number of each type of HSCT in 2017

Department of Hematology and the Department of Pediatric Oncology, 33 hospitalized HSCT patients and those who have been referred for HSCT, are reviewed for clinical management and decisions regarding their eligibility for HSCT. The transplant unit is staffed by 24 nurses trained in oncology and specialized supportive care for HSCT patients. The nursing unit has been assuming leadership in an effort to facilitate improved care for graft-versus-host disease (GVHD), and the establishment of a Long-term Follow-up Unit (LTFU) for the education of patients and their family members. In 2017, 394 patients visited our LTFU clinic. At the weekly 12B ward meeting on Friday afternoons, hospitalized HSCT patients are reviewed in detail by all transplant team members including doctors, nurses, pharmacists, the nutritional support team, clinical research coordinators, and hematopoietic cell transplant coordinator (HCTC).

Research activities and Clinical trials

 We published the results of a prospective single-center study of pneumococcal polysaccharide vaccination in allogeneic hematopoietic stem cell transplantation recipients (Okinaka et al., Microbes Infect 2017). We also published an increased incidence of oral and gastrointestinal secondary cancer after allogeneic hematopoietic stem cell transplantation (Tanaka et al., BMT 2017). We developed a new modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger, which can be applied as risk-adapted management strategies including allogeneic transplantation (Fuji et al., Hematologica 2017). In 2017, we published 35 articles in peer-reviewed international journals.

List of papers published in January 2017 - March 2018

Journal

 1. Okinaka K, Akeda Y, Kurosawa S, Fuji S, Tajima K, Oishi K, Fukuda T. Pneumococcal polysaccharide vaccination in allogeneic hematopoietic stem cell transplantation recipients: a prospective single-center study. Microbes Infect, 19:553-559, 2017

 2. Tanaka Y, Kurosawa S, Tajima K, Tanaka T, Ito R, Inoue Y, Okinaka K, Inamoto Y, Fuji S, Kim SW, Tanosaki R, Yamashita T, Fukuda T. Increased incidence of oral and gastrointestinal secondary cancer after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 52:789-791, 2017

 3. Fuji S, Yamaguchi T, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Owatari S, Miyagi T, Taguchi J, Choi I, Otsuka E, Nakachi S, Yamamoto H, Kurosawa S, Tobinai K, Fukuda T. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation. Haematologica, 102:1258-1265, 2017

 4. Kurosawa S, Oshima K, Yamaguchi T, Yanagisawa A, Fukuda T, Kanamori H, Mori T, Takahashi S, Kondo T, Kohno A, Miyamura K, Umemoto Y, Teshima T, Taniguchi S, Yamashita T, Inamoto Y, Kanda Y, Okamoto S, Atsuta Y. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant, 23:1749-1758, 2017

 5. Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica, 102:614-625, 2017

 6. Inamoto Y, Martin PJ, Paczesny S, Tabellini L, Momin AA, Mumaw CL, Flowers MED, Lee SJ, Carpenter PA, Storer BE, Hanash S, Hansen JA. Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant, 23:1250-1256, 2017

 7. Kawashima I, Inamoto Y, Maeshima AM, Nomoto J, Tajima K, Honda T, Shichijo T, Kawajiri A, Takemura T, Onishi A, Ito A, Tanaka T, Fuji S, Kurosawa S, Kim SW, Maruyama D, Tobinai K, Kobayashi Y, Fukuda T. Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 24:294-300, 2018

 8. Kawajiri A, Fuji S, Tanaka Y, Kono C, Hirakawa T, Tanaka T, Ito R, Inoue Y, Okinaka K, Kurosawa S, Inamoto Y, Kim SW, Yamashita T, Fukuda T. Clinical impact of hyperglycemia on days 0-7 after allogeneic stem cell transplantation. Bone Marrow Transplant, 52:1156-1163, 2017

 9. Ino K, Fuji S, Tajima K, Tanaka T, Okinaka K, Inamoto Y, Kurosawa S, Kim SW, Katayama N, Fukuda T. Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 23:1780-1787, 2017

10. Shinohara A, Inamoto Y, Kurosawa S, Hiramoto N, Ueda R, Tanaka T, Tada K, Kobayashi Y, Morikawa N, Okinaka K, Kim SW, Tajima K, Fukuda T. High non-relapse mortality and low relapse incidence in gender-mismatched allogeneic hematopoietic stem cell transplantation from a parous female donor with a male child. Leuk Lymphoma, 58:578-585, 2017

11. Fuji S, Maeshima AM, Kim SW, Fukuda T. Significant nutrient deposition in the liver after allogeneic hematopoietic stem cell transplantation: pathological analysis of 25 autopsy cases. Bone Marrow Transplant, 52:781-782, 2017

12. Ohmoto A, Fuji S, Miyagi-Maeshima A, Kim SW, Tajima K, Tanaka T, Okinaka K, Kurosawa S, Inamoto Y, Taniguchi H, Fukuda T. Association between pretransplant iron overload determined by bone marrow pathological analysis and bacterial infection. Bone Marrow Transplant, 52:1201-1203, 2017

13. Ogata M, Oshima K, Ikebe T, Takano K, Kanamori H, Kondo T, Ueda Y, Mori T, Hashimoto H, Ogawa H, Eto T, Ueki T, Miyamoto T, Ichinohe T, Atsuta Y, Fukuda T. Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 52:1563-1570, 2017

14. Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, Fuji S, Kohno A, Saito T, Aoyama Y, Hatanaka K, Katayama Y, Yakushijin K, Matsui T, Yamamori M, Takami A, Hino M, Fukuda T. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials. Int J Hematol, 105:485-496, 2017

15. Yui S, Kurosawa S, Yamaguchi H, Kanamori H, Ueki T, Uoshima N, Mizuno I, Shono K, Usuki K, Chiba S, Nakamura Y, Yanada M, Kanda J, Tajika K, Gomi S, Fukunaga K, Wakita S, Ryotokuji T, Fukuda T, Inokuchi K. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. Ann Hematol, 96:1641-1652, 2017

16. Terada K, Yamaguchi H, Ueki T, Usuki K, Kobayashi Y, Tajika K, Gomi S, Kurosawa S, Miyadera K, Tokura T, Omori I, Marumo A, Fujiwara Y, Yui S, Ryotokuji T, Osaki Y, Arai K, Kitano T, Kosaka F, Wakita S, Tamai H, Fukuda T, Inokuchi K. Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor. Ann Hematol, 97:51-61, 2018

17. Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, Kanamori H, Nishikawa A, Nougawa M, Ohashi K, Okumura H, Tanimoto M, Fukuda T, Kawashima N, Kato T, Okada K, Nagafuji K, Okamoto SI, Atsuta Y, Hino M, Tanaka J, Miyamura K. Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. Int J Hematol, 107:211-221, 2018

18. Miyamoto T, Fukuda T, Nakashima M, Henzan T, Kusakabe S, Kobayashi N, Sugita J, Mori T, Kurokawa M, Mori SI. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program. Biol Blood Marrow Transplant, 23:938-944, 2017

19. Ueki T, Hoshi K, Hiroshima Y, Sumi M, Ichikawa N, Ogata M, Satou T, Fukuda T, Kobayashi H. Analysis of five cases of human herpesvirus-6 myelitis among 121 cord blood transplantations. Int J Hematol, 107:363-372, 2018

20. Yanada M, Kurosawa S, Kobayashi T, Ozawa Y, Kanamori H, Kobayashi N, Sawa M, Nakamae H, Uchida N, Hashimoto H, Fukuda T, Hirokawa M, Atsuta Y, Yano S. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study. Bone Marrow Transplant, 52:818-824, 2017

21. Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, Mizuta S, Yamaguchi T, Uchida N, Kouzai Y, Aotsuka N, Ogawa H, Kanamori H, Nishiwaki K, Miyakoshi S, Onizuka M, Amano I, Fukuda T, Ichinohe T, Atsuta Y, Murata M, Teshima T. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplant, 52:1261-1267, 2017

22. Konuma T, Miyazaki Y, Uchida N, Ohashi K, Kondo T, Nakamae H, Takahashi S, Mori T, Ozawa Y, Kato C, Iwato K, Fukuda T, Ichinohe T, Atsuta Y, Ishiyama K. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8. Biol Blood Marrow Transplant, 23:75-80, 2017

23. Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, Suzuki R, Fukuda T, Miyamoto T, Kato K, Nakamae H, Goto H, Eto T, Inoue M, Mori T, Terui K, Onizuka M, Koh K, Koga Y, Ichinohe T, Sawada A, Atsuta Y, Suzumiya J. Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation. Int J Hematol, 105:369-376, 2017

24. Yamasaki S, Hirakawa A, Aoki J, Uchida N, Fukuda T, Ogawa H, Ohashi K, Kondo T, Eto T, Kanamori H, Okumura H, Iwato K, Ichinohe T, Kanda J, Onizuka M, Kuwatsuka Y, Yanada M, Atsuta Y, Takami A, Yano S. Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia. Ann Hematol, 96:289-297, 2017

25. Yokoyama H, Kanda J, Fuji S, Kim SW, Fukuda T, Najima Y, Ohno H, Uchida N, Ueda Y, Eto T, Iwato K, Kobayashi H, Ozawa Y, Kondo T, Ichinohe T, Atsuta Y, Kanda Y. Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen. Biol Blood Marrow Transplant, 23:300-309, 2017

26. Yamasaki S, Suzuki R, Hatano K, Fukushima K, Iida H, Morishima S, Suehiro Y, Fukuda T, Uchida N, Uchiyama H, Ikeda H, Yokota A, Tsukasaki K, Yamaguchi H, Kuroda J, Nakamae H, Adachi Y, Matsuoka KI, Nakamura Y, Atsuta Y, Suzumiya J. Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma. Bone Marrow Transplant, 52:969-976, 2017

27. Nakasone H, Fuji S, Yakushijin K, Onizuka M, Shinohara A, Ohashi K, Miyamura K, Uchida N, Takanashi M, Ichinohe T, Atsuta Y, Fukuda T, Ogata M. Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. Am J Hematol, 92:171-178, 2017

28. Terakura S, Wake A, Inamoto Y, Murata M, Sakai R, Yamaguchi T, Takahashi S, Uchida N, Onishi Y, Ohashi K, Ozawa Y, Kanamori H, Yamaguchi H, Fukuda T, Ichinohe T, Takanashi M, Atsuta Y, Teshima T. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transplant, 52:423-430, 2017

29. Konuma T, Kondo T, Yamashita T, Uchida N, Fukuda T, Ozawa Y, Ohashi K, Ogawa H, Kato C, Takahashi S, Kanamori H, Eto T, Nakaseko C, Kohno A, Ichinohe T, Atsuta Y, Takami A, Yano S. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. Ann Hematol, 96:469-478, 2017

30. Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, Kawakita T, Mori T, Hoshino T, Onizuka M, Ozawa Y, Yoshida S, Ueda Y, Mizuno I, Atsuta Y, Mizuta S. Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults. Br J Haematol, 178:106-111, 2017

31. Fujiwara H, Fuji S, Wake A, Kato K, Takatsuka Y, Fukuda T, Taguchi J, Uchida N, Miyamoto T, Hidaka M, Miyazaki Y, Tomoyose T, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Utsunomiya A. Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study. Bone Marrow Transplant, 52:484-488, 2017

32. Mori J, Yanada M, Uchida N, Fukuda T, Sakura T, Hidaka M, Watakabe-Inamoto K, Kanamori H, Ogawa H, Ichinohe T, Tanaka J, Atsuta Y, Yano S. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17. Biol Blood Marrow Transplant, 23:1398-1404, 2017

33. Kawamura K, Kako S, Mizuta S, Ishiyama K, Aoki J, Yano S, Fukuda T, Uchida N, Ozawa Y, Eto T, Iwato K, Kanamori H, Kahata K, Kondo T, Sawa M, Ichinohe T, Atsuta Y, Kanda Y. Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. Biol Blood Marrow Transplant, 23:2079-2087, 2017

34. Uchino K, Mizuno S, Sato-Otsubo A, Nannya Y, Mizutani M, Horio T, Hanamura I, Espinoza JL, Onizuka M, Kashiwase K, Morishima Y, Fukuda T, Kodera Y, Doki N, Miyamura K, Mori T, Ogawa S, Takami A. Toll-like receptor genetic variations in bone marrow transplantation. Oncotarget, 8:45670-45686, 2017

35. Horio T, Mizuno S, Uchino K, Mizutani M, Hanamura I, Espinoza JL, Onizuka M, Kashiwase K, Morishima Y, Fukuda T, Kodera Y, Doki N, Miyamura K, Mori T, Takami A. The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. Transpl Immunol, 42:34-39, 2017

36. Tomizawa D, Tanaka S, Kondo T, Hashii Y, Arai Y, Kudo K, Taga T, Fukuda T, Goto H, Inagaki J, Koh K, Ohashi K, Ozawa Y, Inoue M, Kato K, Tanaka J, Atsuta Y, Adachi S, Ishida H. Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia. Biol Blood Marrow Transplant, 23:1515-1522, 2017

37. Kondo T, Nagamura-Inoue T, Tojo A, Nagamura F, Uchida N, Nakamae H, Fukuda T, Mori T, Yano S, Kurokawa M, Ueno H, Kanamori H, Hashimoto H, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Ohashi K. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. Am J Hematol, 92:902-908, 2017

38. Shigematsu A, Kako S, Mitsuhashi K, Iwato K, Uchida N, Kanda Y, Fukuda T, Sawa M, Senoo Y, Ogawa H, Miyamura K, Takada S, Nagamura-Inoue T, Morishima Y, Ichinohe T, Atsuta Y, Mizuta S, Tanaka J. Allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia who had central nervous system involvement: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Int J Hematol, 105:805-811, 2017

39. Murata M, Maeda Y, Masuko M, Onishi Y, Endo T, Terakura S, Ishikawa Y, Iriyama C, Ushijima Y, Goto T, Fujii N, Tanimoto M, Kobayashi H, Shibasaki Y, Fukuhara N, Inamoto Y, Suzuki R, Kodera Y, Matsushita T, Kiyoi H, Naoe T, Nishida T. Phase II study of intrabone single unit cord blood transplantation for hematological malignancies. Cancer Sci, 108:1634-1639, 2017

40. Harada K, Doki N, Aoki J, Mori J, Machida S, Masuko M, Uchida N, Najima Y, Fukuda T, Kanamori H, Ogawa H, Ota S, Ogawa K, Takahashi S, Kasai M, Maeda A, Nagafuji K, Kawakita T, Ichinohe T, Atsuta Y. Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15). Haematologica, 103:e69-e72, 2018

41. Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, Kurosawa S, Toya T, Kanamori H, Ozawa Y, Ogawa H, Henzan H, Iwato K, Sakura T, Ota S, Fukuda T, Ichinohe T, Atsuta Y, Yano S. Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma, 59:601-609, 2018

42. Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, Hidaka M, Kobayashi N, Iwato K, Sakura T, Onizuka M, Ozawa Y, Eto T, Kurokawa M, Kahata K, Uchida N, Atsuta Y, Mizuta S, Kako S. Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults. Am J Hematol, 93:47-57, 2018

43. Muta T, Miyamoto T, Kamimura T, Kanda Y, Nohgawa M, Ueda Y, Iwato K, Sasaki O, Mori T, Uchida N, Iida S, Fukuda T, Atsuta Y, Sunami K. Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan. Acta Haematol, 139:35-44, 2018